Literature DB >> 8163047

Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs.

R L Engerman1, T S Kern, M E Larson.   

Abstract

To evaluate the role of excessive polyol pathway activity in the pathogenesis of nerve disorders in diabetes mellitus, nerve conduction velocity was measured in motor nerves of diabetic dogs given an aldose reductase inhibitor (Sorbinil) or placebo, and also in non-diabetic dogs made experimentally galactosaemic. The nerve conduction velocity slowly declined in the diabetic placebo group, becoming significantly less than normal by the fifth year of the study, and the decline was prevented by administration of the aldose reductase inhibitor. Non-diabetic dogs made galactosaemic by consuming a 30% galactose diet developed erythrocyte and nerve polyol concentrations many times greater than that of diabetic or normal animals, but the nerve conduction velocity remained normal throughout 5 years of study. These results in dogs suggest that aldose reductase inhibitors may prevent defective nerve conduction in long-term diabetes, and raise the possibility that excessive accumulation of polyol itself is not sufficient to produce the nerve defect in the absence of excessive polyol utilization.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8163047     DOI: 10.1007/s001250050084

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  19 in total

1.  Evaluation of a modified Sumner's method (dinitrosalicylic acid) for determination of glucose in urine.

Authors:  R BRODERSEN; H T RICKETTS
Journal:  J Lab Clin Med       Date:  1949-10

2.  The effects of sorbinil on peripheral nerve conduction velocity, polyol concentrations and morphology in the streptozotocin-diabetic rat.

Authors:  N E Cameron; M B Leonard; I S Ross; P H Whiting
Journal:  Diabetologia       Date:  1986-03       Impact factor: 10.122

3.  Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats.

Authors:  J H Mayer; D R Tomlinson
Journal:  Diabetologia       Date:  1983-11       Impact factor: 10.122

4.  Random-effects models for longitudinal data.

Authors:  N M Laird; J H Ware
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

5.  Coexistence of nerve conduction deficit with increased Na(+)-K(+)-ATPase activity in galactose-fed mice. Implications for polyol pathway and diabetic neuropathy.

Authors:  N A Calcutt; D R Tomlinson; S Biswas
Journal:  Diabetes       Date:  1990-06       Impact factor: 9.461

6.  Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs.

Authors:  R L Engerman; T S Kern
Journal:  Diabetes       Date:  1993-06       Impact factor: 9.461

7.  Progression of incipient diabetic retinopathy during good glycemic control.

Authors:  R L Engerman; T S Kern
Journal:  Diabetes       Date:  1987-07       Impact factor: 9.461

8.  Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil.

Authors:  A A Sima; V Bril; V Nathaniel; T A McEwen; M B Brown; S A Lattimer; D A Greene
Journal:  N Engl J Med       Date:  1988-09-01       Impact factor: 91.245

9.  Normalization of Na(+)-K(+)-ATPase activity in isolated membrane fraction from sciatic nerves of streptozocin-induced diabetic rats by dietary myo-inositol supplementation in vivo or protein kinase C agonists in vitro.

Authors:  J Kim; H Kyriazi; D A Greene
Journal:  Diabetes       Date:  1991-05       Impact factor: 9.461

10.  The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats.

Authors:  D K Yue; M A Hanwell; P M Satchell; J R Turtle
Journal:  Diabetes       Date:  1982-09       Impact factor: 9.461

View more
  20 in total

Review 1.  Oxidative stress and diabetic complications.

Authors:  Ferdinando Giacco; Michael Brownlee
Journal:  Circ Res       Date:  2010-10-29       Impact factor: 17.367

Review 2.  Diabetic periodontitis: a model for activated innate immunity and impaired resolution of inflammation.

Authors:  Hamdy Nassar; Alpdogan Kantarci; Thomas E van Dyke
Journal:  Periodontol 2000       Date:  2007       Impact factor: 7.589

3.  Genetic and epigenetic modifications in the pathogenesis of diabetic retinopathy: a molecular link to regulate gene expression.

Authors:  Priya Pradhan; Nisha Upadhyay; Archana Tiwari; Lalit P Singh
Journal:  New Front Ophthalmol       Date:  2016-10-24

Review 4.  Diabetes and stroke: part one--risk factors and pathophysiology.

Authors:  Bantwal Suresh Baliga; Jesse Weinberger
Journal:  Curr Cardiol Rep       Date:  2006-02       Impact factor: 2.931

Review 5.  Diabetic neuropathy: clinical features, etiology, and therapy.

Authors:  David Podwall; Clifton Gooch
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

6.  Caloric restriction counteracts age-related changes in the activities of sorbitol metabolizing enzymes from mouse liver.

Authors:  Kevork Hagopian; Jon J Ramsey; Richard Weindruch
Journal:  Biogerontology       Date:  2008-10-25       Impact factor: 4.277

Review 7.  The role of polyols in the pathophysiology of hypergalactosemia.

Authors:  G T Berry
Journal:  Eur J Pediatr       Date:  1995       Impact factor: 3.183

8.  Lipid peroxidation and total antioxidant capacity in vitreous, aqueous humor, and blood samples from patients with diabetic retinopathy.

Authors:  Raffaele Mancino; Donato Di Pierro; Chiara Varesi; Angelica Cerulli; Alessandra Feraco; Claudio Cedrone; Maria Dolores Pinazo-Duran; Massimiliano Coletta; Carlo Nucci
Journal:  Mol Vis       Date:  2011-05-07       Impact factor: 2.367

Review 9.  Oxidative stress and diabetic retinopathy.

Authors:  Renu A Kowluru; Pooi-See Chan
Journal:  Exp Diabetes Res       Date:  2007

10.  A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers.

Authors:  Robert C Fang; Robert D Galiano
Journal:  Biologics       Date:  2008-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.